TDMS Study 05044-02 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus 4-VINYL-1-CYCLOHEXENE DIEPOXIDE DATE: 09/06/94
EXPERIMENT: 05044 TEST: 02 TIME: 19:37:21
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: N01-CP-95653 ROUTE: DERMAL,SOLUTION NTP C#: 60139A
PATHOLOGIST: M. RYAN CAS: 106-87-6
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus 4-VINYL-1-CYCLOHEXENE DIEPOXIDE DATE: 09/06/94
EXPERIMENT: 05044 TEST: 02 TIME: 19:37:21
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-CP-95653 ROUTE: DERMAL,SOLUTION NTP C#: 60139A
PATHOLOGIST: M. RYAN CAS: 106-87-6
MICE(B6C3F1)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Gland
Bone Marrow
Brain
Clitoral Gland
Epididymis
Gallbladder
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus 4-VINYL-1-CYCLOHEXENE DIEPOXIDE DATE: 09/06/94
EXPERIMENT: 05044 TEST: 02 TIME: 19:37:21
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-CP-95653 ROUTE: DERMAL,SOLUTION NTP C#: 60139A
PATHOLOGIST: M. RYAN CAS: 106-87-6
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
====================================================================================================
MALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Harderian Gland Adenoma
Carcinoma or Adenoma
Liver Hemangiosarcoma
Hepatocellular Adenoma
Hepatocellular Carcinoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung Alveolar/Bronchiolar Adenoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
Skin Basosquamous Tumor Malignant
Squamous Cell Carcinoma
Trichoepithelioma, Kertatocanthoma, Squamous Cell Carcinoma,
Basal Cell Carcinoma or Adenoma, Papilloma Squamous, or Papilloma
Spleen Hemangiosarcoma
All Organs Hemangiosarcoma
Hemangiosarcoma or Hemangioma
Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus 4-VINYL-1-CYCLOHEXENE DIEPOXIDE DATE: 09/06/94
EXPERIMENT: 05044 TEST: 02 TIME: 19:37:21
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-CP-95653 ROUTE: DERMAL,SOLUTION NTP C#: 60139A
PATHOLOGIST: M. RYAN CAS: 106-87-6
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
====================================================================================================
FEMALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Adrenal Gland: Non-medullary, Non-cortical
Adenoma
Harderian Gland Adenoma
Carcinoma or Adenoma
Lung Alveolar/Bronchiolar Adenoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
Mammary Gland Carcinoma
Ovary Granulosa Cell Tumor Benign
Granulosa Cell Tumor Malignant
Granulosa Cell Tumor, Benign, Malignant, NOS
Mixed Tumor Benign
Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma
Carcinoma or Adenoma
Skin Squamous Cell Carcinoma
Trichoepithelioma, Kertatocanthoma, Squamous Cell Carcinoma,
Basal Cell Carcinoma or Adenoma, Papilloma Squamous, or Papilloma
All Organs Hemangiosarcoma or Hemangioma
Malignant Lymphoma And Histiocytic Sarcoma
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed,
NOS, or Undifferentiated Cell Type
Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Adrenal Gland: Non-medullary, Non-cortical |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 5/50 (10%) 3/49 (6%) 1/50 (2%) | 2/50 (4%) 1/50 (2%) 7/50 (14%) 3/50 (6%) |
|ADJUSTED (b) | 13.2% 14.3% 32.1% 3.7% | 4.8% 2.6% 19.3% 8.5% |
|TERMINAL (d) | 5/38 (13%) 5/35 (14%) 1/4 (25%) 0/0 | 2/42 (5%) 1/39 (3%) 6/35 (17%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | 729 (T) 729 (T) 520 505 | 593 (T) 593 (T) 572 487 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.055 P=0.579 P=0.104 P=0.398 | P=0.024 * P=0.526N P=0.048 * P=0.237 |
|INCIDENTAL TUMOR | P=0.568 P=0.579 P=0.424 P=0.974 | P=0.194 P=0.526N P=0.074 P=0.642 |
|LOGISTIC REGRESSION | P=0.626N P=0.579 P=0.636N P=0.829 | P=0.173 P=0.526N P=0.061 P=0.492 |
|COCHRAN-ARMITAGE | P=0.056N | P=0.264 |
|FISHER EXACT | P=0.630N P=0.369N P=0.102N | P=0.500N P=0.080 P=0.500 |
|=================================================================================================================================|
| |
|Harderian Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 7/50 (14%) 3/50 (6%) 4/50 (8%) | 5/50 (10%) 1/50 (2%) 4/50 (8%) 8/50 (16%) |
|ADJUSTED (b) | 7.1% 19.3% 34.2% 46.3% | 11.9% 2.6% 10.3% 35.4% |
|TERMINAL (d) | 1/38 (3%) 6/35 (17%) 1/4 (25%) 0/0 | 5/42 (12%) 1/39 (3%) 2/35 (6%) 2/12 (17%) |
|FIRST INCIDENCE (DAYS) | 495 673 520 486 | 593 (T) 593 (T) 464 464 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.141 P=0.230 P=0.008 ** | P=0.001 ** P=0.121N P=0.595N P=0.009 ** |
|INCIDENTAL TUMOR | P=0.477 P=0.187 P=0.550N P=0.397N | P=0.155 P=0.121N P=0.489N P=0.271 |
|LOGISTIC REGRESSION | P=0.260 P=0.155 P=0.627 P=0.484 | P=0.044 * P=0.121N P=0.528N P=0.142 |
|COCHRAN-ARMITAGE | P=0.517N | P=0.078 |
|FISHER EXACT | P=0.159 P=0.661N P=0.500 | P=0.102N P=0.500N P=0.277 |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Harderian Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 7/50 (14%) 4/50 (8%) 4/50 (8%) | 5/50 (10%) 2/50 (4%) 4/50 (8%) 8/50 (16%) |
|ADJUSTED (b) | 7.1% 19.3% 37.9% 46.3% | 11.9% 5.1% 10.3% 35.4% |
|TERMINAL (d) | 1/38 (3%) 6/35 (17%) 1/4 (25%) 0/0 | 5/42 (12%) 2/39 (5%) 2/35 (6%) 2/12 (17%) |
|FIRST INCIDENCE (DAYS) | 495 673 520 486 | 593 (T) 593 (T) 464 464 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.141 P=0.102 P=0.008 ** | P=0.002 ** P=0.247N P=0.595N P=0.009 ** |
|INCIDENTAL TUMOR | P=0.452 P=0.187 P=0.550N P=0.397N | P=0.171 P=0.247N P=0.489N P=0.271 |
|LOGISTIC REGRESSION | P=0.212 P=0.155 P=0.435 P=0.484 | P=0.058 P=0.247N P=0.528N P=0.142 |
|COCHRAN-ARMITAGE | P=0.533N | P=0.103 |
|FISHER EXACT | P=0.159 P=0.500 P=0.500 | P=0.218N P=0.500N P=0.277 |
|=================================================================================================================================|
| |
|Liver |
| Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 5/50 (10%) 0/50 (0%) 0/50 (0%) | 0/50 (0%) 0/50 (0%) 1/50 (2%) 1/50 (2%) |
|ADJUSTED (b) | 2.6% 13.8% 0.0% 0.0% | 0.0% 0.0% 2.8% 2.5% |
|TERMINAL (d) | 1/38 (3%) 4/35 (11%) 0/4 (0%) 0/0 | 0/42 (0%) 0/39 (0%) 0/35 (0%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | 729 (T) 698 --- --- | --- --- 584 474 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.360 P=0.089 P=0.916N (e) | P=0.134 (e) P=0.469 P=0.477 |
|INCIDENTAL TUMOR | P=0.655 P=0.155 P=0.916N (e) | P=0.612 (e) P=0.846 P=0.765 |
|LOGISTIC REGRESSION | P=0.584 P=0.098 P=0.916N (e) | P=0.241 (e) P=0.488 P=0.546 |
|COCHRAN-ARMITAGE | P=0.104N | P=0.236 |
|FISHER EXACT | P=0.102 P=0.500N P=0.500N | (e) P=0.500 P=0.500 |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Liver |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/50 (4%) 1/50 (2%) 0/50 (0%) | 0/50 (0%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|ADJUSTED (b) | 4.7% 5.0% 4.8% 0.0% | 0.0% 0.0% 2.9% 0.0% |
|TERMINAL (d) | 0/38 (0%) 1/35 (3%) 0/4 (0%) 0/0 | 0/42 (0%) 0/39 (0%) 1/35 (3%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | 600 470 672 --- | --- --- 593 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.545N P=0.680 P=0.635N (e) | P=0.576 (e) P=0.464 (e) |
|INCIDENTAL TUMOR | P=0.023N* P=0.541 P=0.112N P=0.125N | P=0.576 (e) P=0.464 (e) |
|LOGISTIC REGRESSION | P=0.129N P=0.690N P=0.525N P=0.238N | P=0.576 (e) P=0.464 (e) |
|COCHRAN-ARMITAGE | P=0.125N | P=0.694 |
|FISHER EXACT | P=0.691N P=0.500N P=0.247N | (e) P=0.500 (e) |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 18/50 (36%) 8/50 (16%) 11/50 (22%) 1/50 (2%) | 8/50 (16%) 6/50 (12%) 5/50 (10%) 3/50 (6%) |
|ADJUSTED (b) | 43.7% 21.8% 55.8% 14.3% | 19.0% 14.8% 14.3% 14.5% |
|TERMINAL (d) | 15/38 (39%) 7/35 (20%) 0/4 (0%) 0/0 | 8/42 (19%) 5/39 (13%) 5/35 (14%) 1/12 (8%) |
|FIRST INCIDENCE (DAYS) | 574 525 435 572 | 593 (T) 457 593 (T) 495 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.153 P=0.034N* P=0.016 * P=0.280 | P=0.565N P=0.441N P=0.402N P=0.591 |
|INCIDENTAL TUMOR | P=0.002N** P=0.055N P=0.219N P=0.122N | P=0.314N P=0.451N P=0.402N P=0.431N |
|LOGISTIC REGRESSION | P=0.006N** P=0.020N* P=0.264N P=0.188N | P=0.174N P=0.416N P=0.402N P=0.299N |
|COCHRAN-ARMITAGE | P<0.001N** | P=0.073N |
|FISHER EXACT | P=0.020N* P=0.093N P<0.001N** | P=0.387N P=0.277N P=0.100N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 5/50 (10%) 4/50 (8%) 4/50 (8%) | 2/50 (4%) 3/50 (6%) 3/50 (6%) 2/50 (4%) |
|ADJUSTED (b) | 14.7% 12.5% 12.4% 25.9% | 4.7% 7.7% 8.6% 10.5% |
|TERMINAL (d) | 4/38 (11%) 2/35 (6%) 0/4 (0%) 0/0 | 1/42 (2%) 3/39 (8%) 3/35 (9%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | 587 590 543 452 | 569 593 (T) 593 (T) 562 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.002 ** P=0.525N P=0.341 P=0.004 ** | P=0.190 P=0.467 P=0.428 P=0.337 |
|INCIDENTAL TUMOR | P=0.110N P=0.487N P=0.531N P=0.397N | P=0.587N P=0.565 P=0.567 P=0.203N |
|LOGISTIC REGRESSION | P=0.083N P=0.504N P=0.470N P=0.671 | P=0.387 P=0.479 P=0.467 P=0.561 |
|COCHRAN-ARMITAGE | P=0.298N | P=0.544N |
|FISHER EXACT | P=0.500N P=0.370N P=0.370N | P=0.500 P=0.500 P=0.691N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 23/50 (46%) 12/50 (24%) 15/50 (30%) 4/50 (8%) | 10/50 (20%) 9/50 (18%) 8/50 (16%) 5/50 (10%) |
|ADJUSTED (b) | 53.3% 30.0% 61.5% 25.9% | 23.3% 22.3% 22.9% 23.5% |
|TERMINAL (d) | 18/38 (47%) 8/35 (23%) 0/4 (0%) 0/0 | 9/42 (21%) 8/39 (21%) 8/35 (23%) 1/12 (8%) |
|FIRST INCIDENCE (DAYS) | 574 525 435 452 | 569 457 593 (T) 495 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.008 ** P=0.039N* P=0.010 * P=0.008 ** | P=0.307 P=0.567N P=0.561N P=0.361 |
|INCIDENTAL TUMOR | P<0.001N** P=0.036N* P=0.177N P=0.024N* | P=0.329N P=0.522N P=0.482N P=0.185N |
|LOGISTIC REGRESSION | P<0.001N** P=0.019N* P=0.232N P=0.085N | P=0.299N P=0.539N P=0.487N P=0.403N |
|COCHRAN-ARMITAGE | P<0.001N** | P=0.096N |
|FISHER EXACT | P=0.018N* P=0.074N P<0.001N** | P=0.500N P=0.398N P=0.131N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 23/50 (46%) 12/50 (24%) 15/50 (30%) 4/50 (8%) | 10/50 (20%) 9/50 (18%) 8/50 (16%) 5/50 (10%) |
|ADJUSTED (b) | 53.3% 30.0% 61.5% 25.9% | 23.3% 22.3% 22.9% 23.5% |
|TERMINAL (d) | 18/38 (47%) 8/35 (23%) 0/4 (0%) 0/0 | 9/42 (21%) 8/39 (21%) 8/35 (23%) 1/12 (8%) |
|FIRST INCIDENCE (DAYS) | 574 525 435 452 | 569 457 593 (T) 495 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.008 ** P=0.039N* P=0.010 * P=0.008 ** | P=0.307 P=0.567N P=0.561N P=0.361 |
|INCIDENTAL TUMOR | P<0.001N** P=0.036N* P=0.177N P=0.024N* | P=0.329N P=0.522N P=0.482N P=0.185N |
|LOGISTIC REGRESSION | P<0.001N** P=0.019N* P=0.232N P=0.085N | P=0.299N P=0.539N P=0.487N P=0.403N |
|COCHRAN-ARMITAGE | P<0.001N** | P=0.096N |
|FISHER EXACT | P=0.018N* P=0.074N P<0.001N** | P=0.500N P=0.398N P=0.131N |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 8/50 (16%) 9/50 (18%) 8/50 (16%) 2/50 (4%) | 3/50 (6%) 5/50 (10%) 8/50 (16%) 6/50 (12%) |
|ADJUSTED (b) | 19.8% 24.3% 85.0% 42.9% | 7.1% 12.8% 21.2% 36.6% |
|TERMINAL (d) | 6/38 (16%) 7/35 (20%) 3/4 (75%) 0/0 | 3/42 (7%) 5/39 (13%) 6/35 (17%) 4/12 (33%) |
|FIRST INCIDENCE (DAYS) | 587 698 572 572 | 593 (T) 593 (T) 495 444 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.442 P<0.001 ** P<0.001 ** | P=0.002 ** P=0.316 P=0.061 P=0.008 ** |
|INCIDENTAL TUMOR | P=0.412 P=0.541 P=0.188 P=0.488N | P=0.025 * P=0.316 P=0.091 P=0.023 * |
|LOGISTIC REGRESSION | P=0.215 P=0.489 P=0.250 P=0.724N | P=0.077 P=0.316 P=0.083 P=0.135 |
|COCHRAN-ARMITAGE | P=0.032N* | P=0.200 |
|FISHER EXACT | P=0.500 P=0.607N P=0.046N* | P=0.357 P=0.100 P=0.243 |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/50 (4%) 1/50 (2%) 1/50 (2%) | 1/50 (2%) 4/50 (8%) 3/50 (6%) 1/50 (2%) |
|ADJUSTED (b) | 5.3% 5.7% 3.2% 4.3% | 2.4% 10.3% 8.0% 6.3% |
|TERMINAL (d) | 2/38 (5%) 2/35 (6%) 0/4 (0%) 0/0 | 1/42 (2%) 4/39 (10%) 2/35 (6%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | 729 (T) 729 (T) 613 510 | 593 (T) 593 (T) 497 579 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.103 P=0.665 P=0.575 P=0.366 | P=0.343 P=0.158 P=0.254 P=0.499 |
|INCIDENTAL TUMOR | P=0.629 P=0.665 P=0.706 P=0.974 | P=0.589N P=0.158 P=0.260 P=0.764N |
|LOGISTIC REGRESSION | P=0.625 P=0.665 P=0.638N P=0.792 | P=0.593N P=0.158 P=0.294 P=0.616 |
|COCHRAN-ARMITAGE | P=0.337N | P=0.431N |
|FISHER EXACT | P=0.691N P=0.500N P=0.500N | P=0.181 P=0.309 P=0.753N |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 10/50 (20%) 11/50 (22%) 9/50 (18%) 3/50 (6%) | 4/50 (8%) 9/50 (18%) 11/50 (22%) 7/50 (14%) |
|ADJUSTED (b) | 24.8% 29.7% 85.5% 45.3% | 9.5% 23.1% 28.4% 40.6% |
|TERMINAL (d) | 8/38 (21%) 9/35 (26%) 3/4 (75%) 0/0 | 4/42 (10%) 9/39 (23%) 8/35 (23%) 4/12 (33%) |
|FIRST INCIDENCE (DAYS) | 587 698 572 510 | 593 (T) 593 (T) 495 444 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.431 P<0.001 ** P<0.001 ** | P=0.002 ** P=0.089 P=0.024 * P=0.005 ** |
|INCIDENTAL TUMOR | P=0.399 P=0.520 P=0.172 P=0.513N | P=0.047 * P=0.089 P=0.036 * P=0.040 * |
|LOGISTIC REGRESSION | P=0.237 P=0.487 P=0.312 P=0.747 | P=0.111 P=0.089 P=0.036 * P=0.118 |
|COCHRAN-ARMITAGE | P=0.021N* | P=0.310 |
|FISHER EXACT | P=0.500 P=0.500N P=0.036N* | P=0.117 P=0.045 * P=0.262 |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) | 1/50 (2%) 1/50 (2%) 3/50 (6%) 4/50 (8%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 0.0% | 2.4% 2.6% 8.2% 23.6% |
|TERMINAL (d) | 0/38 (0%) 0/35 (0%) 0/4 (0%) 0/0 | 1/42 (2%) 1/39 (3%) 2/35 (6%) 1/12 (8%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- | 593 (T) 593 (T) 579 578 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) | P=0.002 ** P=0.745 P=0.251 P=0.013 * |
|INCIDENTAL TUMOR | (e) (e) (e) (e) | P=0.108 P=0.745 P=0.381 P=0.345 |
|LOGISTIC REGRESSION | (e) (e) (e) (e) | P=0.010 * P=0.745 P=0.276 P=0.035 * |
|COCHRAN-ARMITAGE | (e) | P=0.075 |
|FISHER EXACT | (e) (e) (e) | P=0.753N P=0.309 P=0.181 |
|=================================================================================================================================|
| |
|Ovary |
| Granulosa Cell Tumor Benign |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | | 0/50 (0%) 0/49 (0%) 5/49 (10%) 10/50 (20%) |
|ADJUSTED (b) | | 0.0% 0.0% 14.7% 35.3% |
|TERMINAL (d) | | 0/42 (0%) 0/38 (0%) 5/34 (15%) 2/12 (17%) |
|FIRST INCIDENCE (DAYS) | | --- --- 593 (T) 388 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P<0.001 ** (e) P=0.018 * P<0.001 ** |
|INCIDENTAL TUMOR | | P<0.001 ** (e) P=0.018 * P=0.012 * |
|LOGISTIC REGRESSION | | P<0.001 ** (e) P=0.018 * P=0.002 ** |
|COCHRAN-ARMITAGE | | P<0.001 ** |
|FISHER EXACT | | (e) P=0.027 * P<0.001 ** |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Ovary |
| Granulosa Cell Tumor Malignant |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | | 0/50 (0%) 0/49 (0%) 2/49 (4%) 2/50 (4%) |
|ADJUSTED (b) | | 0.0% 0.0% 5.5% 16.7% |
|TERMINAL (d) | | 0/42 (0%) 0/38 (0%) 1/34 (3%) 2/12 (17%) |
|FIRST INCIDENCE (DAYS) | | --- --- 579 593 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.006 ** (e) P=0.206 P=0.035 * |
|INCIDENTAL TUMOR | | P=0.033 * (e) P=0.374 P=0.035 * |
|LOGISTIC REGRESSION | | P=0.015 * (e) P=0.218 P=0.035 * |
|COCHRAN-ARMITAGE | | P=0.087 |
|FISHER EXACT | | (e) P=0.242 P=0.247 |
|=================================================================================================================================|
| |
|Ovary |
| Granulosa Cell Tumor, Benign, Malignant, NOS |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | | 0/50 (0%) 0/49 (0%) 7/49 (14%) 12/50 (24%) |
|ADJUSTED (b) | | 0.0% 0.0% 19.8% 48.2% |
|TERMINAL (d) | | 0/42 (0%) 0/38 (0%) 6/34 (18%) 4/12 (33%) |
|FIRST INCIDENCE (DAYS) | | --- --- 579 388 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P<0.001 ** (e) P=0.004 ** P<0.001 ** |
|INCIDENTAL TUMOR | | P<0.001 ** (e) P=0.008 ** P<0.001 ** |
|LOGISTIC REGRESSION | | P<0.001 ** (e) P=0.006 ** P<0.001 ** |
|COCHRAN-ARMITAGE | | P<0.001 ** |
|FISHER EXACT | | (e) P=0.006 ** P<0.001 ** |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Ovary |
| Mixed Tumor Benign |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | | 0/50 (0%) 0/49 (0%) 11/49 (22%) 6/50 (12%) |
|ADJUSTED (b) | | 0.0% 0.0% 30.0% 28.2% |
|TERMINAL (d) | | 0/42 (0%) 0/38 (0%) 9/34 (26%) 2/12 (17%) |
|FIRST INCIDENCE (DAYS) | | --- --- 497 474 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P<0.001 ** (e) P<0.001 ** P=0.001 ** |
|INCIDENTAL TUMOR | | P=0.002 ** (e) P<0.001 ** P=0.034 * |
|LOGISTIC REGRESSION | | P=0.001 ** (e) P<0.001 ** P=0.012 * |
|COCHRAN-ARMITAGE | | P=0.005 ** |
|FISHER EXACT | | (e) P<0.001 ** P=0.013 * |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/43 (2%) 0/47 (0%) 0/42 (0%) 0/38 (0%) | 17/49 (35%) 16/48 (33%) 5/47 (11%) 0/45 (0%) |
|ADJUSTED (b) | 2.9% 0.0% 0.0% 0.0% | 41.5% 41.0% 14.3% 0.0% |
|TERMINAL (d) | 1/34 (3%) 0/33 (0%) 0/3 (0%) 0/0 | 17/41 (41%) 16/39 (41%) 4/33 (12%) 0/11 (0%) |
|FIRST INCIDENCE (DAYS) | 729 (T) --- --- --- | 593 (T) 593 (T) 566 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.779N P=0.506N P=0.938N (e) | P<0.001N** P=0.574N P=0.015N* P=0.013N* |
|INCIDENTAL TUMOR | P=0.779N P=0.506N P=0.938N (e) | P<0.001N** P=0.574N P=0.009N** P=0.013N* |
|LOGISTIC REGRESSION | P=0.779N P=0.506N P=0.938N (e) | P<0.001N** P=0.574N P=0.009N** P=0.013N* |
|COCHRAN-ARMITAGE | P=0.322N | P<0.001N** |
|FISHER EXACT | P=0.478N P=0.506N P=0.531N | P=0.529N P=0.005N** P<0.001N** |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/43 (2%) 0/47 (0%) 0/42 (0%) 0/38 (0%) | 17/49 (35%) 16/48 (33%) 6/47 (13%) 0/45 (0%) |
|ADJUSTED (b) | 2.9% 0.0% 0.0% 0.0% | 41.5% 41.0% 17.2% 0.0% |
|TERMINAL (d) | 1/34 (3%) 0/33 (0%) 0/3 (0%) 0/0 | 17/41 (41%) 16/39 (41%) 5/33 (15%) 0/11 (0%) |
|FIRST INCIDENCE (DAYS) | 729 (T) --- --- --- | 593 (T) 593 (T) 566 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.779N P=0.506N P=0.938N (e) | P=0.002N** P=0.574N P=0.031N* P=0.013N* |
|INCIDENTAL TUMOR | P=0.779N P=0.506N P=0.938N (e) | P<0.001N** P=0.574N P=0.019N* P=0.013N* |
|LOGISTIC REGRESSION | P=0.779N P=0.506N P=0.938N (e) | P<0.001N** P=0.574N P=0.019N* P=0.013N* |
|COCHRAN-ARMITAGE | P=0.322N | P<0.001N** |
|FISHER EXACT | P=0.478N P=0.506N P=0.531N | P=0.529N P=0.011N* P<0.001N** |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Intermedia |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/43 (2%) 0/47 (0%) 0/42 (0%) 0/38 (0%) | 2/49 (4%) 0/48 (0%) 0/47 (0%) 1/45 (2%) |
|ADJUSTED (b) | 2.9% 0.0% 0.0% 0.0% | 4.9% 0.0% 0.0% 9.1% |
|TERMINAL (d) | 1/34 (3%) 0/33 (0%) 0/3 (0%) 0/0 | 2/41 (5%) 0/39 (0%) 0/33 (0%) 1/11 (9%) |
|FIRST INCIDENCE (DAYS) | 729 (T) --- --- --- | 593 (T) --- --- 593 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.779N P=0.506N P=0.938N (e) | P=0.619 P=0.249N P=0.287N P=0.577 |
|INCIDENTAL TUMOR | P=0.779N P=0.506N P=0.938N (e) | P=0.619 P=0.249N P=0.287N P=0.577 |
|LOGISTIC REGRESSION | P=0.779N P=0.506N P=0.938N (e) | P=0.619 P=0.249N P=0.287N P=0.577 |
|COCHRAN-ARMITAGE | P=0.322N | P=0.482N |
|FISHER EXACT | P=0.478N P=0.506N P=0.531N | P=0.253N P=0.258N P=0.532N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Skin |
| Basosquamous Tumor Malignant |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 0/50 (0%) 3/50 (6%) | 0/50 (0%) 0/50 (0%) 1/50 (2%) 1/50 (2%) |
|ADJUSTED (b) | 0.0% 5.7% 0.0% 16.3% | 0.0% 0.0% 2.9% 3.7% |
|TERMINAL (d) | 0/38 (0%) 2/35 (6%) 0/4 (0%) 0/0 | 0/42 (0%) 0/39 (0%) 1/35 (3%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | --- 729 (T) --- 486 | --- --- 593 (T) 541 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.220 (e) P=0.024 * | P=0.106 (e) P=0.464 P=0.407 |
|INCIDENTAL TUMOR | P=0.101 P=0.220 (e) P=0.514 | P=0.298 (e) P=0.464 P=0.765 |
|LOGISTIC REGRESSION | P=0.060 P=0.220 (e) P=0.154 | P=0.202 (e) P=0.464 P=0.496 |
|COCHRAN-ARMITAGE | P=0.097 | P=0.236 |
|FISHER EXACT | P=0.247 (e) P=0.121 | (e) P=0.500 P=0.500 |
|=================================================================================================================================|
| |
|Skin |
| Squamous Cell Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 14/50 (28%) 40/50 (80%) 43/50 (86%) | 0/50 (0%) 6/50 (12%) 37/50 (74%) 43/50 (86%) |
|ADJUSTED (b) | 0.0% 35.7% 100.0% 100.0% | 0.0% 15.4% 94.8% 100.0% |
|TERMINAL (d) | 0/38 (0%) 10/35 (29%) 4/4 (100%) 0/0 | 0/42 (0%) 6/39 (15%) 33/35 (94%) 12/12 (100%)|
|FIRST INCIDENCE (DAYS) | --- 525 411 376 | --- 593 (T) 402 376 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.014 * P<0.001 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.014 * P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.014 * P<0.001 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** P<0.001 ** | P=0.013 * P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Skin |
| Trichoepithelioma, Kertatocanthoma, Squamous Cell Carcinoma, |
| Basal Cell Carcinoma or Adenoma, Papilloma Squamous, or Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 14/50 (28%) 40/50 (80%) 43/50 (86%) | 0/50 (0%) 6/50 (12%) 37/50 (74%) 43/50 (86%) |
|ADJUSTED (b) | 0.0% 35.7% 100.0% 100.0% | 0.0% 15.4% 94.8% 100.0% |
|TERMINAL (d) | 0/38 (0%) 10/35 (29%) 4/4 (100%) 0/0 | 0/42 (0%) 6/39 (15%) 33/35 (94%) 12/12 (100%)|
|FIRST INCIDENCE (DAYS) | --- 525 411 376 | --- 593 (T) 402 376 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.014 * P<0.001 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.014 * P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.014 * P<0.001 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** P<0.001 ** | P=0.013 * P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
| |
|Spleen |
| Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 1/50 (2%) 1/50 (2%) 0/50 (0%) | 2/50 (4%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 2.9% 3.2% 0.0% | 4.8% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/37 (0%) 1/35 (3%) 0/4 (0%) 0/0 | 2/42 (5%) 0/39 (0%) 0/35 (0%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | --- 729 (T) 613 --- | 593 (T) --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.299 P=0.489 P=0.444 (e) | P=0.191N P=0.255N P=0.279N P=0.538N |
|INCIDENTAL TUMOR | P=0.691 P=0.489 P=0.623 (e) | P=0.191N P=0.255N P=0.279N P=0.538N |
|LOGISTIC REGRESSION | P=0.675 P=0.489 P=0.499 (e) | P=0.191N P=0.255N P=0.279N P=0.538N |
|COCHRAN-ARMITAGE | P=0.592N | P=0.115N |
|FISHER EXACT | P=0.505 P=0.505 (e) | P=0.247N P=0.247N P=0.247N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Spleen |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/49 (6%) 0/50 (0%) 1/50 (2%) 0/50 (0%) | 0/50 (0%) 1/50 (2%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 7.2% 0.0% 4.8% 0.0% | 0.0% 2.5% 0.0% 0.0% |
|TERMINAL (d) | 1/37 (3%) 0/35 (0%) 0/4 (0%) 0/0 | 0/42 (0%) 0/39 (0%) 0/35 (0%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | 600 --- 672 --- | --- 576 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.446N P=0.130N P=0.586N (e) | P=0.692N P=0.490 (e) (e) |
|INCIDENTAL TUMOR | P=0.043N* P=0.281N P=0.106N P=0.125N | P=0.257N P=0.718 (e) (e) |
|LOGISTIC REGRESSION | P=0.101N P=0.117N P=0.350N P=0.169N | P=0.612N P=0.495 (e) (e) |
|COCHRAN-ARMITAGE | P=0.084N | P=0.567N |
|FISHER EXACT | P=0.117N P=0.301N P=0.117N | P=0.500 (e) (e) |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 1/50 (2%) 0/50 (0%) | 3/50 (6%) 0/50 (0%) 1/50 (2%) 3/50 (6%) |
|ADJUSTED (b) | 2.6% 2.9% 25.0% 0.0% | 7.1% 0.0% 2.9% 21.9% |
|TERMINAL (d) | 1/38 (3%) 1/35 (3%) 1/4 (25%) 0/0 | 3/42 (7%) 0/39 (0%) 1/35 (3%) 2/12 (17%) |
|FIRST INCIDENCE (DAYS) | 729 (T) 729 (T) 729 (T) --- | 593 (T) --- 593 (T) 579 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.374 P=0.743 P=0.225 (e) | P=0.082 P=0.135N P=0.372N P=0.133 |
|INCIDENTAL TUMOR | P=0.374 P=0.743 P=0.225 (e) | P=0.187 P=0.135N P=0.372N P=0.309 |
|LOGISTIC REGRESSION | P=0.374 P=0.743 P=0.225 (e) | P=0.133 P=0.135N P=0.372N P=0.211 |
|COCHRAN-ARMITAGE | P=0.311N | P=0.423 |
|FISHER EXACT | P=0.753N P=0.753N P=0.500N | P=0.121N P=0.309N P=0.661N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 0/50 (0%) 1/49 (2%) 0/48 (0%) | 2/49 (4%) 1/49 (2%) 2/50 (4%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 7.7% 0.0% | 4.9% 2.6% 5.7% 0.0% |
|TERMINAL (d) | 0/37 (0%) 0/35 (0%) 0/4 (0%) 0/0 | 2/41 (5%) 1/39 (3%) 2/35 (6%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- 695 --- | 593 (T) 593 (T) 593 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.344 (e) P=0.287 (e) | P=0.472N P=0.517N P=0.637 P=0.532N |
|INCIDENTAL TUMOR | P=0.958 (e) (e) (e) | P=0.472N P=0.517N P=0.637 P=0.532N |
|LOGISTIC REGRESSION | P=0.541 (e) P=0.413 (e) | P=0.472N P=0.517N P=0.637 P=0.532N |
|COCHRAN-ARMITAGE | P=0.692 | P=0.195N |
|FISHER EXACT | (e) P=0.500 (e) | P=0.500N P=0.684N P=0.242N |
|=================================================================================================================================|
| |
|All Organs |
| Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 6/50 (12%) 1/50 (2%) 0/50 (0%) | 4/50 (8%) 0/50 (0%) 1/50 (2%) 1/50 (2%) |
|ADJUSTED (b) | 5.3% 16.6% 3.2% 0.0% | 9.1% 0.0% 2.8% 2.5% |
|TERMINAL (d) | 2/38 (5%) 5/35 (14%) 0/4 (0%) 0/0 | 3/42 (7%) 0/39 (0%) 0/35 (0%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | 729 (T) 698 613 --- | 451 --- 584 474 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.208 P=0.113 P=0.575 (e) | P=0.341N P=0.074N P=0.231N P=0.459N |
|INCIDENTAL TUMOR | P=0.660 P=0.183 P=0.706 (e) | P=0.064N P=0.079N P=0.122N P=0.202N |
|LOGISTIC REGRESSION | P=0.660 P=0.126 P=0.638N (e) | P=0.165N P=0.062N P=0.184N P=0.175N |
|COCHRAN-ARMITAGE | P=0.060N | P=0.163N |
|FISHER EXACT | P=0.134 P=0.500N P=0.247N | P=0.059N P=0.181N P=0.181N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 15
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 3/50 (6%) 1/50 (2%) 0/50 (0%) | 1/50 (2%) 1/50 (2%) 1/50 (2%) 0/50 (0%) |
|ADJUSTED (b) | 9.7% 7.8% 4.8% 0.0% | 2.4% 2.5% 2.9% 0.0% |
|TERMINAL (d) | 2/38 (5%) 2/35 (6%) 0/4 (0%) 0/0 | 1/42 (2%) 0/39 (0%) 1/35 (3%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | 600 470 672 --- | 593 (T) 576 593 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.423N P=0.529N P=0.543N (e) | P=0.535N P=0.747 P=0.721 P=0.748N |
|INCIDENTAL TUMOR | P=0.018N* P=0.651N P=0.100N P=0.125N | P=0.268N P=0.658N P=0.721 P=0.748N |
|LOGISTIC REGRESSION | P=0.039N* P=0.500N P=0.243N P=0.145N | P=0.432N P=0.754 P=0.721 P=0.748N |
|COCHRAN-ARMITAGE | P=0.025N* | P=0.311N |
|FISHER EXACT | P=0.500N P=0.181N P=0.059N | P=0.753N P=0.753N P=0.500N |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma or Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 9/50 (18%) 2/50 (4%) 0/50 (0%) | 5/50 (10%) 1/50 (2%) 2/50 (4%) 1/50 (2%) |
|ADJUSTED (b) | 12.2% 23.9% 7.8% 0.0% | 11.4% 2.5% 5.6% 2.5% |
|TERMINAL (d) | 3/38 (8%) 7/35 (20%) 0/4 (0%) 0/0 | 4/42 (10%) 0/39 (0%) 1/35 (3%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | 600 470 613 --- | 451 576 584 474 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.415 P=0.167 P=0.650 (e) | P=0.288N P=0.123N P=0.288N P=0.381N |
|INCIDENTAL TUMOR | P=0.066N P=0.166 P=0.213N P=0.125N | P=0.029N* P=0.084N P=0.182N P=0.161N |
|LOGISTIC REGRESSION | P=0.072N P=0.189 P=0.309N P=0.136N | P=0.105N P=0.106N P=0.230N P=0.110N |
|COCHRAN-ARMITAGE | P=0.007N** | P=0.092N |
|FISHER EXACT | P=0.194 P=0.218N P=0.028N* | P=0.102N P=0.218N P=0.102N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 16
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|All Organs |
| Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) | 0/50 (0%) 2/50 (4%) 1/50 (2%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 0.0% | 0.0% 4.6% 2.2% 0.0% |
|TERMINAL (d) | 0/38 (0%) 0/35 (0%) 0/4 (0%) 0/0 | 0/42 (0%) 1/39 (3%) 0/35 (0%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- | --- 415 436 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) | P=0.562N P=0.229 P=0.492 (e) |
|INCIDENTAL TUMOR | (e) (e) (e) (e) | P=0.251N P=0.212 P=0.500 (e) |
|LOGISTIC REGRESSION | (e) (e) (e) (e) | P=0.416N P=0.253 P=0.551 (e) |
|COCHRAN-ARMITAGE | (e) | P=0.461N |
|FISHER EXACT | (e) (e) (e) | P=0.247 P=0.500 (e) |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma And Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 6/50 (12%) 2/50 (4%) 1/50 (2%) | 17/50 (34%) 7/50 (14%) 6/50 (12%) 1/50 (2%) |
|ADJUSTED (b) | 7.9% 15.8% 11.5% 2.1% | 39.5% 16.7% 15.5% 2.8% |
|TERMINAL (d) | 3/38 (8%) 4/35 (11%) 0/4 (0%) 0/0 | 16/42 (38%) 5/39 (13%) 4/35 (11%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | 729 (T) 609 635 315 | 534 415 436 499 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.054 P=0.215 P=0.240 P=0.500 | P=0.006N** P=0.029N* P=0.028N* P=0.033N* |
|INCIDENTAL TUMOR | P=0.610 P=0.245 P=0.737 P=0.557 | P<0.001N** P=0.023N* P=0.016N* P=0.008N** |
|LOGISTIC REGRESSION | P=0.411N P=0.235 P=0.643 P=0.492N | P<0.001N** P=0.021N* P=0.012N* P=0.001N** |
|COCHRAN-ARMITAGE | P=0.114N | P<0.001N** |
|FISHER EXACT | P=0.243 P=0.500N P=0.309N | P=0.017N* P=0.008N** P<0.001N** |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 17
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 6/50 (12%) 2/50 (4%) 1/50 (2%) | 17/50 (34%) 5/50 (10%) 5/50 (10%) 1/50 (2%) |
|ADJUSTED (b) | 7.9% 15.8% 11.5% 2.1% | 39.5% 12.4% 13.6% 2.8% |
|TERMINAL (d) | 3/38 (8%) 4/35 (11%) 0/4 (0%) 0/0 | 16/42 (38%) 4/39 (10%) 4/35 (11%) 0/12 (0%) |
|FIRST INCIDENCE (DAYS) | 729 (T) 609 635 315 | 534 553 569 499 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.054 P=0.215 P=0.240 P=0.500 | P=0.005N** P=0.007N** P=0.013N* P=0.033N* |
|INCIDENTAL TUMOR | P=0.610 P=0.245 P=0.737 P=0.557 | P<0.001N** P=0.005N** P=0.007N** P=0.008N** |
|LOGISTIC REGRESSION | P=0.411N P=0.235 P=0.643 P=0.492N | P<0.001N** P=0.005N** P=0.006N** P=0.001N** |
|COCHRAN-ARMITAGE | P=0.114N | P<0.001N** |
|FISHER EXACT | P=0.243 P=0.500N P=0.309N | P=0.004N** P=0.004N** P<0.001N** |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 31/50 (62%) 26/50 (52%) 23/50 (46%) 7/50 (14%) | 31/50 (62%) 25/50 (50%) 34/50 (68%) 29/50 (58%) |
|ADJUSTED (b) | 68.8% 66.5% 94.5% 77.9% | 72.0% 62.4% 79.0% 88.7% |
|TERMINAL (d) | 24/38 (63%) 22/35 (63%) 3/4 (75%) 0/0 | 30/42 (71%) 24/39 (62%) 26/35 (74%) 9/12 (75%) |
|FIRST INCIDENCE (DAYS) | 495 525 435 486 | 451 457 464 388 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.352N P<0.001 ** P<0.001 ** | P<0.001 ** P=0.254N P=0.066 P<0.001 ** |
|INCIDENTAL TUMOR | P=0.015N* P=0.293N P=0.341N P=0.013N* | P=0.037 * P=0.264N P=0.210 P=0.122 |
|LOGISTIC REGRESSION | P=0.059N P=0.216N P=0.408N P=0.021N* | P=0.093 P=0.203N P=0.193 P=0.298 |
|COCHRAN-ARMITAGE | P<0.001N** | P=0.510 |
|FISHER EXACT | P=0.210N P=0.080N P<0.001N** | P=0.157N P=0.338 P=0.419N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 18
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 25 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 16/50 (32%) 26/50 (52%) 40/50 (80%) 47/50 (94%) | 23/50 (46%) 23/50 (46%) 44/50 (88%) 45/50 (90%) |
|ADJUSTED (b) | 37.8% 59.0% 100.0% 100.0% | 52.3% 54.6% 100.0% 100.0% |
|TERMINAL (d) | 12/38 (32%) 17/35 (49%) 4/4 (100%) 0/0 | 21/42 (50%) 20/39 (51%) 35/35 (100%) 12/12 (100%)|
|FIRST INCIDENCE (DAYS) | 587 470 411 315 | 534 415 402 376 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.032 * P<0.001 ** P<0.001 ** | P<0.001 ** P=0.451 P<0.001 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P=0.042 * P<0.001 ** P<0.001 ** | P<0.001 ** P=0.566 P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P=0.021 * P<0.001 ** P<0.001 ** | P<0.001 ** P=0.505 P<0.001 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P=0.034 * P<0.001 ** P<0.001 ** | P=0.579N P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 35/50 (70%) 40/50 (80%) 42/50 (84%) 47/50 (94%) | 41/50 (82%) 36/50 (72%) 47/50 (94%) 46/50 (92%) |
|ADJUSTED (b) | 77.7% 90.9% 100.0% 100.0% | 91.1% 83.7% 100.0% 100.0% |
|TERMINAL (d) | 28/38 (74%) 31/35 (89%) 4/4 (100%) 0/0 | 38/42 (90%) 32/39 (82%) 35/35 (100%) 12/12 (100%)|
|FIRST INCIDENCE (DAYS) | 495 470 411 315 | 451 415 402 376 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.108 P<0.001 ** P<0.001 ** | P<0.001 ** P=0.377N P=0.003 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P=0.095 P=0.035 * P=0.019 * | P<0.001 ** P=0.241N P=0.005 ** P=0.002 ** |
|LOGISTIC REGRESSION | P<0.001 ** P=0.124 P<0.001 ** P<0.001 ** | P<0.001 ** P=0.242N P=0.003 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P=0.001 ** | P=0.019 * |
|FISHER EXACT | P=0.178 P=0.077 P=0.002 ** | P=0.171N P=0.061 P=0.117 |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 02 PAGE 19
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 85 WEEKS
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).
--multipart-boundary
Content-type: text/plain
Range: bytes 134404-134404/134404
--multipart-boundary--